Inicio > Hematología y Hemoterapia > Grupos sanguíneos y marcadores celulares > Página 5

Grupos sanguíneos y marcadores celulares

Bibliografía.

1. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002; 52:195-215.

2. Jemal A; Thomas A; Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002; 52(1): 23-47.

3. Gao W, Guo CB.Factors associated with diagnostic delay of oral squa¬mous cell carcinoma. J Oral Maxillofac Surg. 2009; 67(5):1015-20.

4. Pitiyage G, Tilakaratne WM, Tavassoli M. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med 2009 ; 38(10):737-52.

5. Campo Trapero J, Cano sanchez J, Palacios-Sanchez B, Sánchez –Gutierrez JJ, Gonzalez-Moles MA, Bascones-Martinez A. Update on Molecular Pathology in Oral Cancer and Precancer Anticancer Research 2008; 28: 1197-1206.

6. Koichiro Yomezawa, Shin Ishiumii, Junko Kitamoto-Matsuda, Takeshi Fujita, Koichi Morimoto, Dsaisuke Yamashita, Miki Saito, Naoki Otsuki, Yasuhiro Irino, Masakazu Shinoara, Masaru Yoshida, Ken-Ichi Nibu. Serum and Tissue Metabolomics of Head and Neck Cancer. Cancer Genomics and Proteomics. 2013;10: 233-238.

7. Rizzolo D, Hanifin C, Chiodo TA. Oral cancer: How to find this hidden killer in two minutes. JAAPA. 2007; 20(10): 42-7.

8. Joseph BK. Oral cancer: prevention and detection. Med Princ Pract. 2002; 11(1):32-5.

9. Schliephake H. Prognostic relevance of molecular markers of oral cancer -A review. J Oral Maxillofac Surg. 2003; 32:233-45.

10. Lovett K, Liang B, Mackey T. Risks of Online Direct-to-Consumer Tumor Markers for Cancer Screening. Journal of clinical Oncology. 2012, 30(13):1411-14.

11. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996; 56:5309–18.

12. Dunn BK, Jegalian K, Greenwald P. Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. Recent Results Cancer Res. 2011; 188:21-47. Review.

13. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Research. 2003; 63(8):1727–30

14. Ferrer-Admetlla A, Sikora M, Laayouni H, et al. A natural history of
FUT2 polymorphism in humans. Mol Biol Evol 2009; 26:1993–2003.

15. Dabelsteen E, Gao,S.. ABO Blood-group Antigens in Oral Cancer. J Dent Res. 2004; 84(1):21-8.

16. Jean-Pierre Cartron. Philippe Rouger. Bases molèculaires des antigènes des groupes sanguins. De l´immunogenètique à la bioilogic cellulaire. 3º Ed. 2001.

17. Storry JR, Olsson ML. The ABO blood group system revisited: a review and update. Immunohematology 2009; 25:48–59.

18. Daniels G. Functions of red cell surface proteins. Vox Sang. 2007; 93:331-40

19. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999; 1473:247–66.

20. Hakomori S. Structure, organization, and function of glycosphingolipids in membrane. Curr Opin Hematol. 2003; 10:16–24

21. Assimakopoulos D; Kolettas E; Patrikakos G, Evangelou, A. The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol Histopathol. 2002; 17(4): 1269-81,

22. Theocharis A, Skandalis S, Tzanakakis G, Karamanos N, “Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting,” FEBS Journal, 2010, 277( 19):3904–23.

23. Daniels G. Functions of red cell surface proteins. Vox Sang, 2007; 93(4): 331-40.

24. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Act. 1999; 1473(1): 247-66.

25. Cartron J, Bailly P, Le Van Kim C: Insights into the structure and function of membrane polypeptides carrying blood group antigens. Vox Sang. 1998, 74:29-64.

26. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS. 2000; 108:1-28.

27. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002; 99:10231-3.

28. Rajeshwari K, Dravid NV, Patil AV, Nikumbh DB, Oswal SJ, Karibasappa GN Tayade YR Rajeshwari K, Dravid NV, Patil AV, Nikumbh DB, Oswal SJ, Karibasappa GN, Tayade YR. Diagnostic Utility of Specific Red Cell Adherence (SRCA) Test in Various Prostatic Lesions. International Journal of Health Sciences & Research. 2013, 3(4): 25-31.

29. Khalili J. Oral cancer: risk factors, prevention and diagnostic. Experimental Oncology. 2008, 30(4): 259–64.

30. Biondi C; Campi C; Escovich L; Racca A; García Borrás S; Cotorruelo C. Loss of A, B, and H antigens in oral cancer. Inmunología. 2008; 27(3): 127-31.

31. Flegel W. ABO genotyping: the quest for clinical applications Blood Transfusion. 2013. 11(1): 6-9..

32. Jun Li, Shuhai Li, Qian Liu, Yu Li, Qinghua Zhou, Shuanghu Yuan, Zhou Wang. Effects of ABO and FUT2 Genetic Transcription Absence on ABH Histo-blood Group Antigen Expression in Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2011; 12: 3201-06.

33. Campi C, Escovich L, Valdés V, García-Borrás S, Racca L, Racca A, et al. Secretor status and ABH antigens expression in patients with oral lesions. Med Oral Patol Oral Cir Bucal. 2007, 12(6):E431-E434.

34. López-Ferrer A, de Bolós C, Barranco C, Garrido M, Isern J, Carlstedt I, et al. Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium. Gut. 2000; 47:349–56.

35. Torrado J; Plummer M; Vivas J; Garay J; Lopez G; Peraza S;et al. Lewis antigen alterations in a population at high risk of stomach cancer. Cancer Epidemiol. Biomarkers Prev. 2000; 9:671-74.